Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Givosiran: A Review in Acute Hepatic Porphyria
Yahiya Y. Syed
Drugs (2021) Vol. 81, Iss. 7, pp. 841-848
Closed Access | Times Cited: 66

Showing 1-25 of 66 citing articles:

RNAi-based therapeutics and tumor targeted delivery in cancer
Göknur Kara, George A. Călin, Bülent Özpolat
Advanced Drug Delivery Reviews (2022) Vol. 182, pp. 114113-114113
Closed Access | Times Cited: 256
Therapeutic siRNA: State-of-the-Art and Future Perspectives
Maik Friedrich, Achim Aigner
BioDrugs (2022) Vol. 36, Iss. 5, pp. 549-571
Open Access | Times Cited: 228
Current Advances in RNA Therapeutics for Human Diseases
Hannah Zogg, Rajan Singh, Seungil Ro
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 5, pp. 2736-2736
Open Access | Times Cited: 127
Small interfering RNA: Discovery, pharmacology and clinical development—An introductory review
Priyanga Ranasinghe, Melisande Addison, James W. Dear, et al.
British Journal of Pharmacology (2022) Vol. 180, Iss. 21, pp. 2697-2720
Open Access | Times Cited: 75
Glycomimetics for the inhibition and modulation of lectins
Steffen Leusmann, Petra Ménová, Elena Shanina, et al.
Chemical Society Reviews (2023) Vol. 52, Iss. 11, pp. 3663-3740
Open Access | Times Cited: 59
Advancements in clinical RNA therapeutics: Present developments and prospective outlooks
Phei Er Saw, Erwei Song
Cell Reports Medicine (2024) Vol. 5, Iss. 5, pp. 101555-101555
Open Access | Times Cited: 19
Delivering living medicines with biomaterials
Tetsuhiro Harimoto, Wei‐Hung Jung, David Mooney
Nature Reviews Materials (2025)
Closed Access | Times Cited: 2
Nanotechnology‐Assisted RNA Delivery: From Nucleic Acid Therapeutics to COVID‐19 Vaccines
Chiara Rinoldi, Seyed Shahrooz Zargarian, Paweł Nakielski, et al.
Small Methods (2021) Vol. 5, Iss. 9
Open Access | Times Cited: 56
Enhancing the Effectiveness of Oligonucleotide Therapeutics Using Cell-Penetrating Peptide Conjugation, Chemical Modification, and Carrier-Based Delivery Strategies
Saeed Anwar, Farin Mir, Toshifumi Yokota
Pharmaceutics (2023) Vol. 15, Iss. 4, pp. 1130-1130
Open Access | Times Cited: 34
Current status and trends in small nucleic acid drug development: Leading the future
Yuxi Miao, Chen Fu, Zhaojin Yu, et al.
Acta Pharmaceutica Sinica B (2024) Vol. 14, Iss. 9, pp. 3802-3817
Open Access | Times Cited: 15
Enhancing RNA-lipid nanoparticle delivery: Organ- and cell-specificity and barcoding strategies
Pu-Sheng Wei, Nagasri Thota, Gresham John, et al.
Journal of Controlled Release (2024) Vol. 375, pp. 366-388
Open Access | Times Cited: 14
Nucleic acid drugs: recent progress and future perspectives
Xiaoyi Sun, Sarra Setrerrahmane, Chencheng Li, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 11
Between hope and reality: treatment of genetic diseases through nucleic acid-based drugs
Virginie Baylot, Thi Khanh Le, David Taïeb, et al.
Communications Biology (2024) Vol. 7, Iss. 1
Open Access | Times Cited: 10
Emergence of Small Interfering RNA-Based Gene Drugs for Various Diseases
Harshini Kurakula, Swetha Vaishnavi, Mohammed Yaseen Sharif, et al.
ACS Omega (2023) Vol. 8, Iss. 23, pp. 20234-20250
Open Access | Times Cited: 21
Inclisiran—Safety and Effectiveness of Small Interfering RNA in Inhibition of PCSK-9
Łukasz Wołowiec, Joanna Osiak, Anna Wołowiec, et al.
Pharmaceutics (2023) Vol. 15, Iss. 2, pp. 323-323
Open Access | Times Cited: 18
The Medicinal Chemistry of Artificial Nucleic Acids and Therapeutic Oligonucleotides
Miklós Bege, Anikó Borbás
Pharmaceuticals (2022) Vol. 15, Iss. 8, pp. 909-909
Open Access | Times Cited: 27
Spotlight on Givosiran as a Treatment Option for Adults with Acute Hepatic Porphyria: Design, Development, and Place in Therapy
Chaudry Nasir Majeed, D. Christopher, Ted Xiao, et al.
Drug Design Development and Therapy (2022) Vol. Volume 16, pp. 1827-1845
Open Access | Times Cited: 25
Dose-Dependent Nuclear Delivery and Transcriptional Repression with a Cell-Penetrant MeCP2
Xizi Zhang, Claudia Cattoglio, Madeline Zoltek, et al.
ACS Central Science (2023) Vol. 9, Iss. 2, pp. 277-288
Open Access | Times Cited: 15
RNA Therapeutics: A Healthcare Paradigm Shift
Sarfaraz K. Niazi
Biomedicines (2023) Vol. 11, Iss. 5, pp. 1275-1275
Open Access | Times Cited: 15
Targeting the Liver with Nucleic Acid Therapeutics for the Treatment of Systemic Diseases of Liver Origin
Anagha Gogate, Jordyn Belcourt, Milan Shah, et al.
Pharmacological Reviews (2023) Vol. 76, Iss. 1, pp. 49-89
Open Access | Times Cited: 12
Cancer theragnostics: closing the loop for advanced personalized cancer treatment through the platform integration of therapeutics and diagnostics
Olga V. Sergeeva, Liang Luo, Anthony Guiseppi‐Elie
Frontiers in Bioengineering and Biotechnology (2025) Vol. 12
Open Access
siRNA-based Delivery Systems: Technologies, Carriers, Applications, and Approved Products
Parisa Ghasemiyeh, Soliman Mohammadi‐Samani
European Journal of Pharmacology (2025), pp. 177441-177441
Closed Access
The Progress and Evolving Trends in Nucleic-Acid-Based Therapies
Yunlong Liu, Changjun Wang, Xiuping Fu, et al.
Biomolecules (2025) Vol. 15, Iss. 3, pp. 376-376
Open Access
Landscape of small nucleic acid therapeutics: moving from the bench to the clinic as next-generation medicines
Mohan Liu, Yusi Wang, Yi-Bing Zhang, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access
MicroRNAs as Sensitizers of Tyrosine Kinase Inhibitor Resistance in Cancer: Small Molecule Partnerships
Alma D. Campos-Parra, David Sánchez-Marín, Víctor Acevedo-Sánchez
Pharmaceuticals (2025) Vol. 18, Iss. 4, pp. 492-492
Open Access
Page 1 - Next Page

Scroll to top